Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer - Discussion

被引：0

|

作者：

Jocham

Tunn

Teillac

机构：

来源：

UROLOGIA INTERNATIONALIS | 1998年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：16 / 17

页数：2

相关论文

共 35 条

[31] A NEW EXTRA LONG-ACTING DEPOT PREPARATION OF THE LHRH ANALOG ZOLADEX - 1ST ENDOCRINOLOGIC AND PHARMACOKINETIC DATA IN PATIENTS WITH ADVANCED PROSTATE-CANCER
DIJKMAN, GA
DELMORAL, PF
PLASMAN, JWMH
KUMS, JJM
DELAERE, KPJ
DEBRUYNE, FMJ
HUTCHINSON, FJ
FURR, BJA
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1990, 37 (06): : 933 - 936
[32] Efficacy and Tolerability of Leuprorelin Acetate (Eligard®) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3-or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer
Ohlmann, Carsten-Henning
Gross-Langenhoff, Marco
UROLOGIA INTERNATIONALIS, 2018, 100 (01) : 66 - 71
[33] Efficacy and tolerability of 3-and 6-month depot formulations of leuprorelin acetate for advanced prostate cancer in treatment-naive and pretreated patients: pooled data from two non-interventional studies.
Ohlmann, Carsten Henning
Gross-Langenhoff, Marco
Tunn, Ulf W.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[34] HEMOSTATIC CHANGES DURING HORMONE MANIPULATION IN ADVANCED PROSTATE-CANCER - A COMPARISON OF DES 3-MG DAY AND GOSERELIN 3.6-MG MONTH
EMTAGE, LA
GEORGE, J
BOUGHTON, BJ
TRETHOWAN, C
BLACKLEDGE, GRP
EUROPEAN JOURNAL OF CANCER, 1990, 26 (03) : 315 - 319
[35] COST COMPARISON BETWEEN LEUPROLIDE 3-MONTH FORMULATION AND GOSERELIN 1-MONTH FORMULATION AS ADJUVANT ENDOCRINE THERAPY IN POST-MASTECTOMY, PREMENOPAUSAL WOMEN WITH EARLY-STAGE, ESTROGEN RECEPTOR-POSITIVE BREAST CANCER WHO ARE AT MODERATE-TO-HIGH RISK OF RECURRENCE IN CHINA
Fan, L.
Wang, Z.
Yeh, Y. C.
Du, F.
Liu, G.
Zheng, C.
Zheng, L.
Gao, X.
VALUE IN HEALTH, 2019, 22 : S473 - S474

← 1 2 3 4 →